These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11897572)

  • 1. Immunotherapy of human papillomavirus-associated malignancies and the challenges posed by T-cell tolerance.
    Wilcox RA; Chen L
    Front Biosci; 2002 Apr; 7():d853-71. PubMed ID: 11897572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site.
    Lamikanra A; Pan ZK; Isaacs SN; Wu TC; Paterson Y
    J Virol; 2001 Oct; 75(20):9654-64. PubMed ID: 11559797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy.
    Eiben GL; Velders MP; Kast WM
    Adv Cancer Res; 2002; 86():113-48. PubMed ID: 12374277
    [No Abstract]   [Full Text] [Related]  

  • 4. The current state of therapeutic and T cell-based vaccines against human papillomaviruses.
    Yang A; Farmer E; Lin J; Wu TC; Hung CF
    Virus Res; 2017 Mar; 231():148-165. PubMed ID: 27932207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunology of human papillomavirus infection in lower genital tract neoplasia.
    Man S; Fiander A
    Best Pract Res Clin Obstet Gynaecol; 2001 Oct; 15(5):701-14. PubMed ID: 11563868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of protein and adjuvant vaccinations on tumour growth.
    Gérard CM; Baudson N; Kraemer K; Bruck C; Garçon N; Paterson Y; Pan ZK; Pardoll D
    Vaccine; 2001 Mar; 19(17-19):2583-9. PubMed ID: 11257396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell-based vaccines for therapy of HPV16-induced tumours.
    Bubeník J; Símová J; Vonka V; Smahel M; Mikysková R; Mendoza L
    Adv Exp Med Biol; 2001; 495():359-63. PubMed ID: 11774593
    [No Abstract]   [Full Text] [Related]  

  • 8. [Perspectives for the development of vaccines and immunotherapy against cervico-uterine cancer].
    Guzmán-Rojas L; Alcocer-González JM; Madrid-Marina V
    Salud Publica Mex; 1998; 40(1):38-46. PubMed ID: 9567657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current status of therapeutic HPV vaccine.
    van Driel WJ; Ressing ME; Brandt RM; Toes RE; Fleuren GJ; Trimbos JB; Kast WM; Melief CJ
    Ann Med; 1996 Dec; 28(6):471-7. PubMed ID: 9017105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
    Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
    J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Papillomavirus: biology and clinical implications for immunotherapy.
    Stanley M
    Mol Med Today; 1997 Jun; 3(6):239-40. PubMed ID: 9211412
    [No Abstract]   [Full Text] [Related]  

  • 12. Papillomavirus virus-like particles as anticancer vaccines.
    Da Silva DM; Velders MP; Rudolf MP; Schiller JT; Kast WM
    Curr Opin Mol Ther; 1999 Feb; 1(1):82-8. PubMed ID: 11249689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice.
    Riezebos-Brilman A; Regts J; Freyschmidt EJ; Dontje B; Wilschut J; Daemen T
    Gene Ther; 2005 Sep; 12(18):1410-4. PubMed ID: 15843807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of human papillomavirus vaccines in cervical neoplasia.
    Stern PL; Faulkner R; Veranes EC; Davidson EJ
    Best Pract Res Clin Obstet Gynaecol; 2001 Oct; 15(5):783-99. PubMed ID: 11563873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do "high-risk" human papillomavirus (HPV) types lead to cancer by evading the immune system?
    Tendler A; Ho GY; Kadish AS
    Gynecol Oncol; 1999 Apr; 73(1):169-70. PubMed ID: 10094902
    [No Abstract]   [Full Text] [Related]  

  • 16. The pathogenesis of advanced cervical cancer provides the basis for an empirical therapeutic vaccine.
    Ghim SJ; Sundberg J; Delgado G; Jenson AB
    Exp Mol Pathol; 2001 Dec; 71(3):181-5. PubMed ID: 11733943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Viruses and cervical cancers].
    Mathevet P
    Rev Prat; 2001 Sep; 51(13):1413-6. PubMed ID: 11601069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Papillomavirus-like particle vaccines for cervical cancer.
    Schiller JT
    Mol Med Today; 1999 May; 5(5):209-15. PubMed ID: 10322313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Papillomaviruses and human tumors].
    Vonka V; Hamsíková E; Sobotková E; Smahel M; Kitasato H; Sainerová H; Ludvíková V; Zák R; Kanka J; Kolár Z; Kovarík J
    Cas Lek Cesk; 2000 Dec; 139 Suppl 1():27-9. PubMed ID: 11262898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination to prevent and treat cervical cancer.
    Roden RB; Ling M; Wu TC
    Hum Pathol; 2004 Aug; 35(8):971-82. PubMed ID: 15297964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.